Digital Therapeutics for Fibromyalgia Global Market Report 2025

The digital therapeutics for fibromyalgia market size has grown exponentially in recent years. It will grow from $0.98 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 21.3%. The growth during the historic period is attributed to increasing clinical recognition of fibromyalgia and earlier diagnosis, a shift toward home-based self-management during the coronavirus pandemic, insurer and employer preference for nonpharmacological pain management, opioid stewardship policies supporting behavioral pain therapies, and rising patient preference for low-risk, non-drug pain interventions.

The digital therapeutics for fibromyalgia market size is expected to see exponential growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 20.9%. The growth during the forecast period is attributed to the expansion of reimbursement for evidence-based digital interventions, increasing integration into rheumatology and primary care pathways, rising prevalence and symptom burden in aging populations, greater emphasis on women’s health and chronic pain equity, and cost-containment pressures to reduce unnecessary imaging and visits. Key trends in the forecast period include prescription digital therapeutics providing acceptance and commitment therapy programs, virtual reality-based pain distraction and rehabilitation modules, augmented reality-guided movement therapy and posture training, artificial intelligence-driven personalization of therapy content and pacing, and natural language processing-powered coaching and symptom triage.

The increasing awareness of digital health solutions is expected to drive the growth of the digital therapeutics for fibromyalgia market in the coming years. Digital health solutions include software-enabled tools and services such as patient apps, patient portals, and virtual-care platforms that provide information, monitoring, and therapy through digital channels. This growing awareness is fueled by government-supported initiatives and widespread adoption of official health apps that normalize online access to care. Digital therapeutics for fibromyalgia leverage these familiar channels to streamline onboarding and adherence to app-based cognitive behavioral therapy, pacing, and sleep programs while allowing clinician oversight. For example, in December 2023, the UK National Health Service reported that digital health app users reached 33.6 million, up from 16.8 million in 2022, with monthly logins increasing 54% from 16.8 million to 25.8 million. This demonstrates how increasing awareness of digital health solutions is propelling the digital therapeutics for fibromyalgia market.

Key companies in the digital therapeutics for fibromyalgia market are focusing on technological advancements, such as computerized behavioral therapy devices, to deliver evidence-based interventions that improve pain management, reduce fatigue, enhance sleep quality, and support mental health through scalable, patient-centric digital platforms. A computerized behavioral therapy device is a software-based platform or application that provides structured, evidence-based cognitive or behavioral therapy interventions remotely, using interactive modules, exercises, and real-time feedback to manage fibromyalgia symptoms. For instance, in May 2023, US-based Swing Therapeutics, Inc. launched Stanza following U.S. FDA De Novo marketing authorization (DEN220083). The program offers a 12-week, self-guided acceptance and commitment therapy (ACT) program for fibromyalgia, with a randomized controlled trial in The Lancet reporting significant clinical improvements. It is delivered via smartphone (iOS or Android), allowing patients to access therapy conveniently at home.

In February 2025, US-based XRHealth Inc., a therapeutic extended reality (XR) and digital therapeutics company, acquired RealizedCare for an undisclosed amount. Through this acquisition, XRHealth aims to integrate RealizedCare’s immersive digital therapeutics content and artificial intelligence triage tool into its platform to expand evidence-based care for chronic pain and behavioral health, including its existing fibromyalgia programs, while scaling AI-enabled, value-based delivery and enhancing clinician oversight and personalization. RealizedCare is a US-based immersive digital therapeutics company specializing in chronic pain and behavioral health.

Major players in the digital therapeutics for fibromyalgia market are Grünenthal GmbH, Hinge Health Inc., DarioHealth Corp., Kaia Health, CogniFit Inc., Big Health Ltd., Remedee Labs, HelloBetter GmbH, AppliedVR Inc., PainDrainer, Swing Therapeutics Inc., Fern Health Inc., JOGO Health Inc., LIN Health Inc., MoreGoodDays, Happify Health Inc., Click Therapeutics Inc., Wellthy Therapeutics Pvt. Ltd., FlexifyMe, SleepioRx.

North America was the largest region in the digital therapeutics for fibromyalgia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The digital therapeutics for fibromyalgia market research report is one of a series of new reports that provides digital therapeutics for fibromyalgia market statistics, including the digital therapeutics for fibromyalgia industry global market size, regional shares, competitors with the digital therapeutics for fibromyalgia market share, detailed digital therapeutics for fibromyalgia market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics for fibromyalgia industry. This digital therapeutics for fibromyalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Digital therapeutics for fibromyalgia are health applications and online programs that provide structured therapy and monitor symptoms to support daily self-management. They aim to reduce pain and fatigue, enhance sleep and functionality, and offer patients and clinicians valuable data for personalized care.

The primary product types of digital therapeutics for fibromyalgia include software applications, devices, and platforms. Software applications are clinically validated programs designed to deliver therapeutic interventions for managing fibromyalgia symptoms such as pain and fatigue. These solutions are available through both online and offline channels. Key applications include chronic pain management, sleep disorder management, fatigue management, and others, with main end users being hospitals, clinics, homecare providers, and others.

The countries covered in the Digital Therapeutics For Fibromyalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics for fibromyalgia market consists of revenues earned by entities by providing services such as remote health coaching and therapist support, tele-physiotherapy consultations, adherence and engagement services, and outcomes analytics and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics for fibromyalgia market also includes sales of cognitive behavioral therapy (cbt) apps, pain neuroscience education modules, digital graded exercise and activity pacing programs, virtual reality-based pain distraction experiences, and sleep hygiene and relaxation programs, clinician dashboards and care coordination tools, patient. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.